학술논문
Abstract 11905: Heparin and Low-molecular-weight Heparin Switch Associated With an Increase in Bleeding Complications in Patients on Apixaban Undergoing Catheter Ablation: The Amper Ablation Study
Document Type
Article
Author
Source
Circulation (Ovid); November 2019, Vol. 140 Issue: Supplement 1 pA11905-A11905, 1p
Subject
Language
ISSN
00097322; 15244539
Abstract
Background:The aim of this study was to identify the factors associated with bleeding complications in patients taking apixaban and undergoing a catheter ablation in everyday clinical practice.Methods:AMPER ABLATION is a multicenter, observational, prospective study of patients with non valvular atrial fibrillation (AF) undergoing a catheter ablation. Eligible patients had been taking apixaban (2.5 or 5 mg twice daily) for ?3 weeks before the procedure, and were followed for 30 days afterwards.Results:A total of 595 patients (65 [interquartile range 59, 72] years, 67% male, mean CHA2DS2-VASc score 1.85 ? 1.37) were enrolled at 25 academic/ non academic centers in France; 524 patients (88%) were receiving apixaban 10 mg/day and 71(12%) 5 mg/day. 323 patients (54%) underwent an AF ablation, and 272 (46%) an atrial flutter (AFL) ablation. The most prevalent concomitant disorders were hypertension (51% of patients), diabetes (15%) and vascular disease (10%). Mean creatinine concentration was 1.06?0.28 mg/dL, median weight was 83?18 kg and mean creatinine clearance (Cockcroft-Gault) was 82?34 mL/min. The management of apixaban in the periprocedural period was left to the investigator?s preference. Overall, 264 patients were switched to unfractionated heparin or enoxaparin (238 for AF ablations and 26 for AFL ablations). The median duration of switch was 29 hours. Complications were reported at 30 days, and included 12 bleeding events (1 tamponade needing drainage, 1 pericardial effusion without drainage, 7 International Society on Thrombosis and Haemostasis [ISTH] non major bleedings for AF ablations and 1 pericardial effusion without drainage, and 2 ISTH nonmajor bleedings for AFL ablations) and 1 embolic event (non disabling stroke for an AF ablation). Comparing patients with andwithout a bleeding event revealed a higher rate of heparin or low-molecular-weight heparin (LMWH) switching in patients with a bleeding event (60% vs 35%; p=0.02). A switch to heparin or LMWH was the only factor associated with an increase rate of bleeding (odds ratio 2.5; [CI 95%;1.1, 7.1; p=0.01).Conclusion:Heparin or LMWH switch in the periprocedural AF and AFL-ablation period is associated with an increased rate of bleeding complications at 30 days.